Hemab Therapeutics (NASDAQ:COAG) Research Coverage Started at Lifesci Capital

Lifesci Capital initiated coverage on shares of Hemab Therapeutics (NASDAQ:COAG) in a research report report published on Monday, MarketBeat reports. The firm issued an outperform rating and a $65.00 price target on the stock.

COAG has been the subject of several other research reports. Wedbush increased their target price on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Rodman & Renshaw initiated coverage on Hemab Therapeutics in a report on Monday, October 12th. They issued a “buy” rating and a $56.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on Hemab Therapeutics in a report on Thursday, October 15th. They issued an “overweight” rating and a $70.00 price target on the stock. HC Wainwright upped their price target on Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group increased their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a report on Monday, July 13th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.00.

Hemab Therapeutics Stock Up 1.4%

Shares of Hemab Therapeutics stock opened at $39.33 on Monday. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $55.42. The business has a fifty day moving average price of $37.23.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.07). On average, sell-side analysts forecast that Hemab Therapeutics will post -3.06 EPS for the current year.

Institutional Trading of Hemab Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new position in shares of Hemab Therapeutics during the 3rd quarter valued at about $46,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Hemab Therapeutics by 77.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,400 shares of the company’s stock worth $209,000 after purchasing an additional 2,800 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Hemab Therapeutics in the second quarter worth about $230,000. Profund Advisors LLC bought a new stake in shares of Hemab Therapeutics in the third quarter worth about $246,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Hemab Therapeutics in the second quarter worth about $688,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company developing treatments for serious bleeding and thrombotic disorders, with a focus on conditions that have limited treatment options. Its research centers on therapies intended to help restore or regulate blood clotting. The company’s lead candidate, HMB-001, is an investigational bispecific antibody being developed for Glanzmann thrombasthenia, a rare inherited bleeding disorder. Hemab is also advancing research into additional disorders affecting hemostasis, the process that helps the body control bleeding.